Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by MyKnighton Jul 12, 2019 8:47am
109 Views
Post# 29912345

GW P

GW Pbeen here for almost 2 years now, never saw that many post....
Something good is coming and a lot of shorters are getting scared, another good sign....

Just to add info Epidiolex from gw pharma, took lest then 5 1/2 years to have all fda phase approved... which mean we could go very quickly.... not 3 years like some others like to mention....for phase 3

You also got to realise that their is some other independant approval process that regulate the planet that will go ahead without fda approval...(Japan/europe...)... and you ll find out that fda process are under the heat to get faster...

GVHD is the name they have an orpean drug that will be fast track.
And more important it WORK.

And regading our debt anything under 500 Millions $, is nothing for the big industry that will grab the GVHD market for themself.... so sitting under 50 millions is really ok with me.

We all knew from the start that this company had to go thru stock dillution to finance this beauty so like i said earlier , 50 Millions is nothing.

A partner is coming...$$$$$
Bullboard Posts